03:39 PM EDT, 07/24/2024 (MT Newswires) -- Skye Bioscience ( SKYE ) is partnering with privately held Beacon Biosignals for devices to monitor brain activity during sleep in some of the participants in an upcoming trial of prospective obesity medication, Beacon said Wednesday.

Skye Bioscience ( SKYE ) said separately it will begin screening participants for a phase 2 trial of its nimacimab drug candidate in August, with around 80 people with obesity divided roughly equally in groups receiving either 200 milligrams of nimacimab or a placebo once a week. Another 40 patients will also receive a dose of Novo Nordisk's (NVO) previously approved Wegovy obesity drug, nimacimab or placebo.

In addition to assessing the efficacy and safety of nimacimab, the study will assess its potential impact on patients' sleep because problems like obstructive sleep apnea are a common comorbidity with obesity. Skye will monitor sleep quality and the frequency of apnea, hypoxia and nocturnal waking in a subgroup at various stages using Beacon's Dreem 3S electroencephalography headband device.

Skye is expecting to provide interim trial data in Q2 2025 and topline results in Q4 2025.

Price: 5.80, Change: -0.26, Percent Change: -4.29